A bold vision involves applying Internet functions to the vaccine lifecycle, covering each stage, from the research to the injection.
Ali Health (00241:HK) and Sinovac Biotech (SVA:Nasdaq) announced cooperation in vaccine-related digital services and products. The two parties will focus on building a digital platform for the combination of the Internet and vaccine, online registration for vaccines, vaccine information tracking, post-injection health monitoring and science popularization education.
Sinovac Biotech will use Ali Health’s Internet platform to extend the business into digital health, industry escalation, tracking code, vaccine registration and other related services. On Ali Health’s side, its immunity planning center will help implement the program based on rich experience in children’s vaccine injection planning and online registration for the HPV vaccine.
The cooperation also includes the establishment of a vaccine platform for COVID-19 viruses. Sinovac Biotech is one of the few companies worldwide that have preceded the COVID-19 vaccine into clinical trials. The company has completed the research for the COVID-19 vaccine in Phase I and Phase II and promoted the Phase III clinical trials in Brazil, Indonesia, Turkey and other countries. The company has established vaccine industrial facilities and plans to reach an annual output of over 300 million kits.